<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="7ffe64e6-051b-4cec-aa71-90a88956d5cc"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <effectiveTime value="20120703"/>
   <setId root="9c9541af-3221-4e6c-a1eb-fae64925a488"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="786036330" root="1.3.6.1.4.1.519.1"/>
            <name>STAT RX USA LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="101822682" root="1.3.6.1.4.1.519.1"/>
                  <name>PSS World Medical Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="786036330" root="1.3.6.1.4.1.519.1"/>
                        <name>STAT RX USA LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="relabel"/>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="repack"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="7cd71aef-f130-45d3-b1a3-23b152027366"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL listing data elements section"/>
               <effectiveTime value="20110321"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="16590-124" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>IBUPROFEN<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>IBUPROFEN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="55111-682" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="400" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="WK2XYI10QM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>IBUPROFEN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="WK2XYI10QM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>IBUPROFEN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARNAUBA WAX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="VH2XOU12IE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYDEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOLS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-124-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="40" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-124-40" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-124-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-124-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20081120"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075682" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">4I</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="16590-125" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>IBUPROFEN<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>IBUPROFEN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="55111-683" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="600" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="WK2XYI10QM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>IBUPROFEN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="WK2XYI10QM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>IBUPROFEN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARNAUBA WAX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="VH2XOU12IE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYDEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOLS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-125-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="40" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-125-40" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-125-50" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-125-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-125-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-125-71" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="120" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-125-72" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20081120"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075682" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">6I</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="16590-126" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>IBUPROFEN<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>IBUPROFEN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="55111-684" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="800" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="WK2XYI10QM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>IBUPROFEN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="WK2XYI10QM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>IBUPROFEN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARNAUBA WAX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="VH2XOU12IE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYDEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOLS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-126-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="40" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-126-40" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-126-50" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-126-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-126-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-126-71" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="120" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-126-72" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20081120"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075682" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">8I</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="816eab88-07cc-426e-9d58-650d16a04517"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <text>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <br/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">BOXED WARNING</content>
                  <paragraph>
                     <content styleCode="bold">Cardiovascular Risk</content>
                  </paragraph>
                  <list listType="unordered" ID="icc76e8cd-6fe6-4943-8873-717e00b5654d">
                     <item>NSAIDs may cause an increased risk of serious cardiovascular thrombotic 
events, myocardial infarction, and stroke,which can be fatal. This risk may 
increase with duration of use. Patients with cardiovascular disease or risk 
factors for cardiovascular disease may be at greater risk (See <content styleCode="bold">
                           <linkHtml href="#section-">  WARNINGS</linkHtml>
                        </content>). </item>
                  </list>
                  <list listType="unordered" ID="i0adefd13-c7f9-4aec-84d2-0f9243e8c296">
                     <item>IBU tablets are contraindicated for treatment of peri-operative pain in the 
setting of coronary artery bypass graft (CABG)surgery (See <content styleCode="bold">
                           <linkHtml href="#section-">  WARNINGS</linkHtml>
                        </content>). </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Gastrointestinal Risk</content>
                  </paragraph>
                  <list listType="unordered" ID="ifdb84e46-c6d9-4256-8b33-7740b481d4f8">
                     <item>NSAIDS cause an increased risk of serious 
gastrointestinal adverse events including bleeding, ulceration, and perforation of 
the stomach or intestines, which can be fatal. These events can occur at any time 
during use and without warning symptoms.Elderly patients are at greater risk for 
serious gastrointestinal events. (See<content styleCode="bold">
                           <content styleCode="bold">
                              <linkHtml href="#section-">WARNINGS</linkHtml>
                           </content>). </content>
                     </item>
                  </list>
                  <br/>
               </text>
               <effectiveTime value="20110321"/>
            </section>
         </component>
         <component>
            <section>
               <id root="928f3fa4-2dbb-4e9a-ad5b-b14476dd2f40"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>IBU tablets contain the active ingredient ibuprofen, which is (±) -2 - (<content styleCode="italics">p</content> - isobutylphenyl) propionic acid. Ibuprofen is a white 
powder with a melting point of 74-77° C and is very slightly soluble in 
water(less than 1 mg/mL) and readily soluble in organic solvents such as ethanol and 
acetone. The structural formula is represented below:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>IBU, a nonsteroidal anti-inflammatory drug (NSAID), is available in 400 mg, 600 
mg, and 800 mg tablets for oral administration.Inactive ingredients: carnauba 
wax, colloidal silicon dioxide,croscarmellose sodium, hypromellose, magnesium 
stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, 
polysorbate,titanium dioxide.</paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20110321"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM1">
                     <text>Structure Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="5aeedc42-6810-4404-8152-81512b87fd68"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>IBU tablets contain ibuprofen which possesses analgesic 
and antipyretic activities. Its mode of action, like that of other NSAIDs, is not 
completely understood, but may be related to prosta gland in 
synthetase inhibition.</paragraph>
                  <paragraph>In clinical studies in patients with rheumatoid arthritis and osteoarthritis, 
Ibuprofen tablets have been shown to be comparable to aspirin in controlling pain 
and inflammation and to be associated with a statistically significant reduction 
in the milder gastrointestinal side effects (see <content styleCode="bold">
                        <linkHtml href="#_4928ac09-3e61-6f5b-e90a-2391436cc932">ADVERSE REACTIONS</linkHtml>
                     </content>). 
Ibuprofen may be well tolerated in some patients who have had gastrointestinal 
side effects with aspirin, but these patients when treated with IBU tablets 
should be carefully followed for signs and symptoms of gastro intestinal ulceration 
and bleeding. Although it is not definitely known whether ibuprofen causes less 
peptic ulceration than aspirin, in one study involving 885 patients with 
rheumatoid arthritis treated for up to one year, there were no reports of gastric 
ulceration with ibuprofen whereas frank ulceration was reported in 13 patients in 
the aspirin group (statistically significant p less than .001).</paragraph>
                  <paragraph>Gastroscopic studies at varying doses show an increased tendency toward 
gastric irritation at higher doses. However, at comparable doses, gastric 
irritation is approximately half that seen with aspirin.Studies using 
51Cr-tagged red cells indicate that fecal blood loss associated with Ibuprofen 
tablets in doses up to 2400 mg daily did not exceed the normal range, and was 
significantly less than that seen in aspirin-treated patients.</paragraph>
                  <paragraph>In clinical studies in patients with rheumatoid arthritis, Ibuprofen has been 
shown to be comparable to indomethacin in controlling the signs and symptoms of 
disease activity and to be associated with a statistically significant reduction 
of the milder gastrointestinal (see <content styleCode="bold">
                        <linkHtml href="#_4928ac09-3e61-6f5b-e90a-2391436cc932">ADVERSE REACTIONS</linkHtml>
                     </content>) and 
CNS side effects.</paragraph>
                  <paragraph>Ibuprofen may be used in combination with gold salts and/or 
corticosteroids.</paragraph>
                  <paragraph>Controlled studies have demonstrated that Ibuprofen is a more effective 
analgesic than propoxyphene for the relief of episiotomy pain, pain following 
dental extraction procedures, and for the relief of the symptoms of primary 
dysmenorrhea.</paragraph>
                  <paragraph>In patients with primary dysmenorrhea, Ibuprofen has been shown to reduce 
elevated levels of prostaglandin activity in the menstrual fluid and to reduce 
resting and active intrauterine pressure, as well as the frequency of uterine 
contractions. The probable mechanism of action is to inhibit prostaglandin 
synthesis rather than simply to provide analgesia.</paragraph>
                  <paragraph>The ibuprofen in IBU tablets is rapidly absorbed. Peak serum ibuprofen levels 
are generally attained one to two hours after administration.With single doses 
up to 800 mg, a linear relationship exists between amount of drug administered 
and the integrated area under the serum drug concentration vs time curve. Above 
800 mg, however,the area under the curve increases less than proportional to 
increases in dose. There is no evidence of drug accumulation or enzyme 
induction.</paragraph>
                  <paragraph>The administration of Ibuprofen tablets either under fasting conditions or 
immediately before meals yields quite similar serum ibuprofen concentration-time 
profiles. When Ibuprofen is administered immediately after a meal, there is a 
reduction in the rate of absorption but no appreciable decrease in the extent of 
absorption.The bio availability of the drug is minimally altered by the presence 
of food.</paragraph>
                  <paragraph>A bio availability study has shown that there was no interference with the 
absorption of ibuprofen when given in conjunction with an antacid containing both 
aluminum hydroxide and magnesium hydroxide.</paragraph>
                  <paragraph>Ibuprofen is rapidly metabolized and eliminated in the urine. The excretion 
of ibuprofen is virtually complete 24 hours after the last dose. The serum 
half-life is 1.8 to 2.0 hours.</paragraph>
                  <paragraph>Studies have shown that following ingestion of the drug, 45% to79% of the 
dose was recovered in the urine within 24 hours as metabolite A (25%), 
(+)-2-[<content styleCode="italics">p</content>-(2hydroxymethyl-propyl) phenyl] propionic 
acid and metabolite B (37%), (+)-2-[<content styleCode="italics">p</content>-(2carboxypropyl)phenyl]propionic acid; the percentages of 
free and conjugated ibuprofen were approximately 1% and 14%, respectively.</paragraph>
               </text>
               <effectiveTime value="20110321"/>
            </section>
         </component>
         <component>
            <section>
               <id root="552c0fe6-62d1-4283-a976-455411b1cccc"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Carefully consider the potential benefits and risks of 
Ibuprofen tablets and other treatment options before deciding to use 
Ibuprofen.Use the lowest effective dose for the shortest duration consistent 
with individual patient treatment goals (see <content styleCode="bold">
                        <linkHtml href="#section-"> WARNINGS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>IBU tablets are indicated for relief of the signs and symptoms of rheumatoid 
arthritis and osteoarthritis.</paragraph>
                  <paragraph>IBU tablets are indicated for relief of mild to moderate pain.</paragraph>
                  <paragraph>IBU tablets are also indicated for the treatment of primary dysmenorrhea.</paragraph>
                  <paragraph>Controlled clinical trials to establish the safety and effectiveness of IBU 
tablets in children have not been conducted.</paragraph>
               </text>
               <effectiveTime value="20110321"/>
            </section>
         </component>
         <component>
            <section>
               <id root="470c2766-5df3-4ace-a13d-74b1b7b0b5b7"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>IBU tablets are contraindicated in patients with known 
hypersensitivity to ibuprofen.</paragraph>
                  <paragraph>IBU tablets should not be given to patients who have experienced asthma, 
urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. 
Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported 
in such patients (see <content styleCode="bold">
                        <linkHtml href="#section-"> WARNINGS, 
Anaphylactoid Reactions,</linkHtml>
                     </content>
                     <content styleCode="bold"> and </content>
                     <content styleCode="bold">
                        <linkHtml href="#section-"> PRECAUTIONS, 
Preexisting Asthma</linkHtml>
                     </content>
                     <content styleCode="bold">).</content>
                  </paragraph>
                  <paragraph>IBU tablets are contraindicated for the treatment of peri-operative pain in 
the setting of coronary artery bypass graft (CABG) surgery(see <content styleCode="bold">
                        <linkHtml href="#section-"> WARNINGS</linkHtml>
                     </content>).<content styleCode="bold"/>
                  </paragraph>
               </text>
               <effectiveTime value="20110321"/>
            </section>
         </component>
         <component>
            <section>
               <id root="25b09db4-d06a-403f-a2b1-386c4c71e64d"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">CARDIOVASCULAR EFFECTS</content>
                  <linkHtml href="#section-"/>
                  <br/>
                  <br/>
                  <content styleCode="bold">Cardiovascular Thrombotic 
Events</content>
                  <paragraph>Clinical trials of several COX-2 selective and non selective 
NSAIDs of up to three years duration have shown an increased risk of 
serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, 
which can be fatal. All NSAIDs, both COX-2 selective and non selective,may have a 
similar risk. Patients with known CV disease or risk factors for CV disease may 
be at greater risk. To minimize the potential risk for an adverse CV event in 
patients treated with an NSAID, the lowest effective dose should be used for the 
shortest duration possible. Physicians and patients should remain alert for 
the development of such events, even in the absence of previous CV symptoms. 
Patients should be informed about the signs and/or symptoms of serious CV events 
and the steps to take if they occur.</paragraph>
                  <paragraph>There is no consistent evidence that concurrent use of aspirin mitigates the 
increased risk of serious CV thrombotic events associated with NSAID use. The 
concurrent use of aspirin and an NSAID does increase the risk of serious GI 
events (see <content styleCode="bold">GI </content>
                     <content styleCode="bold">
                        <linkHtml href="#section-"> WARNINGS)</linkHtml>
                     </content>.</paragraph>
                  <paragraph>Two large, controlled clinical trials of a COX-2 selective NSAID for the 
treatment of pain in the first 10-14 days following CABG surgery found an 
increased incidence of myocardial infarction and stroke (see <content styleCode="bold">
                        <linkHtml href="#section-"> CONTRAINDICATIONS</linkHtml>
                     </content>
                     <content styleCode="bold">).</content>
                  </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Hypertension</content>
                  <paragraph>NSAIDs including IBU tablets, can lead to onset of new 
hypertension or worsening of preexisting hypertension, either of which 
may contribute to the increased incidence of CV events. Patients taking thiazides 
or loop diuretics may have impaired response to these therapies when taking 
NSAIDs. NSAIDs, including IBU tablets, should be used with caution in patients 
with hypertension. Blood pressure (BP)should be monitored closely during the 
initiation of NSAID treatment and throughout the course of therapy.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Congestive Heart Failure and 
Edema</content>
                  <paragraph>Fluid retention and edema have been observed in some patients 
taking NSAIDs. IBU tablets should be used with caution in patients with fluid 
retention or heart failure.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Gastrointestinal Effects - Risk of 
Ulceration, Bleeding, and Perforation</content>
                  <paragraph>NSAIDs, including IBU tablets, can cause serious 
gastrointestinal(GI) adverse events including inflammation, bleeding, 
ulceration, and perforation of the stomach, small intestine, or large intestine, 
which can be fatal. These serious adverse events can occur at any time, with or 
without warning symptoms, in patients treated with NSAIDs. Only one in five 
patients, who develop a serious upper GI adverse event on NSAID therapy, is 
symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs 
occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% 
of patients treated for one year. These trends continue with longer duration of 
use, increasing the likelihood of developing a serious GI event at some time 
during the course of therapy. However, even short-term therapy is not without 
risk. NSAIDs should be prescribed with extreme caution in those with a prior 
history of ulcer disease or gastrointestinal bleeding.Patients with a prior 
history of peptic ulcer disease and/or gastrointestinal bleeding who use NSAIDs 
have a greater than 10-fold increased risk for developing a GI bleed compared to 
patients treated with neither of these risk factors. Other factors that increase 
the risk of GI bleeding in patients treated with NSAIDs include concomitant use 
of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, 
smoking, use of alcohol, older age, and poor general health status. Most 
spontaneous reports of fatal GI events are in elderly or debilitated patients 
and therefore, special care should be taken in treating this population. To 
minimize the potential risk for an adverse GI event in patients treated with an 
NSAID, the lowest effective dose should be used for the shortest possible 
duration. Patients and physicians should remain alert for signs and symptoms of 
GI ulcerations and bleeding during NSAID therapy and promptly initiate additional 
evaluation and treatment if a serious GI event is suspected.This should include 
discontinuation of the NSAID until a serious GI adverse event is ruled out. For 
high-risk patients, alternate therapies that do not involve NSAIDs should be 
considered.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Renal Effects</content>
                  <paragraph>Long-term administration of NSAIDs has resulted in renal 
papillary necrosis and other renal injury. Renal toxicity has also been seen in 
patients in whom renal prostaglandins have a compensatory role in the 
maintenance of renal perfusion. In these patients, administration of a NSAID may 
cause a dose dependent reduction in prostaglandin formation and, secondarily, in 
renal blood flow, which may precipitate overt renal decompensation. Patients at 
greatest risk of this reaction are those with impaired renal function, heart 
failure,liver dysfunction, those taking diuretics and ACE inhibitors, and the 
elderly. Discontinuation of NSAID therapy is usually followed by recovery to the 
pretreatment state.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Advanced Renal Disease</content>
                  <paragraph>No information is available from controlled clinical studies 
regarding the use of Ibuprofen tablets in patients with advanced renal 
disease.Therefore, treatment with IBU tablets is not recommended in these 
patients with advanced renal disease. If IBU tablet therapy must be initiated, 
close monitoring of the patients renal function is advisable.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Anaphylactoid Reactions</content>
                  <paragraph>As with other NSAIDs, anaphylactoid reactions may occur 
inpatients without known prior exposure to IBU tablets. IBU tablets should not 
be given to patients with the aspirin triad. This symptom complex typically 
occurs in asthmatic patients who experience rhinitis with or without nasal 
polyps, or who exhibit severe, potentially fatal broncho spasm after taking 
aspirin or other NSAIDs (see <content styleCode="bold">
                        <linkHtml href="#section-"> CONTRAINDICATIONS</linkHtml>
                     </content>
                     <content styleCode="bold"> and 
</content>
                     <content styleCode="bold">
                        <linkHtml href="#section-"> PRECAUTIONS, Preexisting 
Asthma)</linkHtml>
                     </content>
                     <content styleCode="bold">.</content>Emergency help should be sought in 
cases where an anaphylactoid reaction occurs. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Skin Reactions</content>
                  <paragraph>NSAIDs, including IBU tablets, can cause serious skin adverse 
events such as exfoliative dermatitis, Stevens-Johnson Syndrome(SJS), and toxic 
epidermal necrolysis (TEN), which can be fatal.These serious events may occur 
without warning. Patients should be informed about the signs and symptoms of 
serious skin manifestations and use of the drug should be discontinued at the 
first appearance of skin rash or any other sign of hypersensitivity.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Pregnancy</content>
                  <paragraph>In late pregnancy, as with other NSAIDs, IBU tablets should 
be avoided because it may cause premature closure of the ductus arteriosus.</paragraph>
               </text>
               <effectiveTime value="20110322"/>
            </section>
         </component>
         <component>
            <section>
               <id root="70cfe3ee-a1de-404f-8326-3e207e9218a1"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">General</content>
                  <paragraph>IBU tablets cannot be expected to substitute for corticosteroids 
or to treat corticosteroid insufficiency. Abrupt discontinuation of 
corticosteroids may lead to disease exacerbation. Patients on 
prolonged corticosteroid therapy should have their therapy tapered slowly if 
a decision is made to discontinue corticosteroids.</paragraph>
                  <paragraph>The pharmacological activity of IBU tablets in reducing fever and inflammation 
may diminish the utility of these diagnostic signs in detecting complications of 
presumed noninfectious, painful conditions.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Hepatic effects</content>
                  <paragraph>Borderline elevations of one or more liver tests may occur in 
up to 15% of patients taking NSAIDs, including IBU tablets. These 
laboratory abnormalities may progress, may remain unchanged, or maybe transient 
with continuing therapy. Notable elevations of ALT or AST (approximately three or 
more times the upper limit of normal) have been reported in approximately 1% of 
patients in clinical trials with NSAIDs. In addition, rare cases of severe 
hepatic reactions,including jaundice, fulminant hepatitis, liver necrosis, and 
hepatic failure, some of them with fatal outcomes have been reported. A patient 
with symptoms and/or signs suggesting liver dysfunction, or with abnormal liver 
test values, should be evaluated for evidence of the development of a more severe 
hepatic reaction while on therapy with IBU tablets. If clinical signs and 
symptoms consistent with liver disease develop, or if systemic manifestations 
occur (e.g.,eosinophilia, rash, etc.), IBU tablets should be discontinued.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Hematological effects</content>
                  <paragraph>Anemia is sometimes seen in patients receiving NSAIDs, 
including IBU tablets. This may be due to fluid retention, occult or gross 
GI blood loss, or an incompletely described effect upon erythropoiesis.Patients 
on long-term treatment with NSAIDs, including IBU tablets,should have their 
hemoglobin or hematocrit checked if they exhibit any signs or symptoms of 
anemia.</paragraph>
                  <paragraph>In two post marketing clinical studies the incidence of a decreased hemoglobin 
level was greater than previously reported. Decrease in hemoglobin of 1 gram or 
more was observed in 17.1% of 193patients on 1600 mg ibuprofen daily 
(osteoarthritis), and in 22.8% of189 patients taking 2400 mg of ibuprofen daily 
(rheumatoid arthritis).Positive stool occult blood tests and elevated serum 
creatinine levels were also observed in these studies.</paragraph>
                  <paragraph>NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding 
time in some patients. Unlike aspirin, their effect on platelet function is 
quantitatively less, of shorter duration, and reversible.</paragraph>
                  <paragraph>Patients receiving IBU tablets who may be adversely affected by alterations in 
platelet function, such as those with coagulation dis orders or patients receiving 
anticoagulants should be carefully monitored.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Preexisting asthma</content>
                  <paragraph>Patients with asthma may have aspirin-sensitive asthma. The use of 
aspirin in patients with aspirin-sensitive asthma has been associated with severe 
broncho spasm, which can be fatal. Since cross reactivity,including broncho spasm, 
between aspirin and NSAIDs has been reported in such aspirin-sensitive patients, 
IBU tablets should not be administered to patients with this form of aspirin 
sensitivity and should be used with caution in patients with preexisting 
asthma.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Ophthalmological 
effects</content>.<paragraph>Blurred and/or diminished vision, scotomata, and/or changes 
in color vision have been reported. If a patient develops such complaints while 
receiving IBU tablets, the drug should be discontinued, and the patient should 
have an ophthalmologic examination which includes central visual fields and color 
vision testing.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Aseptic Meningitis</content>
                  <paragraph>Aseptic meningitis with fever and coma has been observed on 
rare occasions in patients on ibuprofen therapy. Although it is probably more 
likely to occur in patients with systemic lupus erythematosus and related 
connective tissue diseases, it has been reported in patients who do not have an 
underlying chronic disease. If signs or symptoms of meningitis develop in a 
patient on IBU tablets, the possibility of its being related to IBU tablets 
should be considered.</paragraph>
               </text>
               <effectiveTime value="20110322"/>
               <component>
                  <section>
                     <id root="f2ed5059-f1dd-4d89-a921-4a8c2da7bf84"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients </title>
                     <text>
                        <paragraph>Patients should be informed of the following information 
before initiating therapy with an NSAID and periodically during the course 
of ongoing therapy. Patients should also be encouraged to read the NSAID 
Medication Guide that accompanies each prescription dispensed</paragraph>
                        <paragraph>• IBU tablets like other NSAIDs, may cause serious CV side effects,such as MI 
or stroke, which may result in hospitalization and even death. Although serious 
CV events can occur without warning symptoms, patients should be alert for the 
signs and symptoms of  chest pain, shortness of breath, weakness, slurring of 
speech, and should ask for medical advice when observing any indicative sign 
or symptoms. Patients should be apprised of the importance of this follow-up (see 
<content styleCode="bold">
                              <linkHtml href="#section-">  WARNINGS,</linkHtml>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#section-">  Cardiovascular 
Effects</linkHtml>
                              </content>).</content>
                        </paragraph>
                        <paragraph>• IBU tablets, like other NSAIDs, can cause GI discomfort and, rarely,serious 
GI side effects, such as ulcers and bleeding, which may result in hospitalization 
and even death. Although serious GI tract ulcerations and bleeding can occur 
without warning symptoms,patients should be alert for the signs and symptoms of 
ulcerations and bleeding, and should ask for medical advice when observing any 
indicative signs or symptoms including epigastric pain, dyspepsia,melena, and 
hematemesis. Patients should be apprised of the importance of this follow-up (see 
<content styleCode="bold">
                              <linkHtml href="#section-">  WARNINGS,</linkHtml>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#section-">  Gastrointestinal Effects-Risk of 
Ulceration</linkHtml>
                              </content>
                              <content styleCode="bold">, </content>
                              <content styleCode="bold">
                                 <linkHtml href="#section-">  Bleeding and 
Perforation)</linkHtml>
                              </content>
                              <content styleCode="bold">.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">• </content>IBU tablets, like other NSAIDs, can cause serious 
skin side effects such as exfoliative dermatitis, SJS and TEN, which may result 
in hospitalization and even death. Although serious skin reactions may occur 
without warning, patients should be alert for the signs and symptoms of skin rash 
and blisters, fever, or other signs of hypersensitivity such as itching, and 
should ask for medical advice when observing any indicative sign or symptoms. 
Patients should be advised to stop the drug immediately if they develop any type 
of rash and contact their physicians as soon as possible.</paragraph>
                        <paragraph>• Patients should promptly report signs or symptoms of unexplained weight gain 
or edema to their physicians.</paragraph>
                        <paragraph>• Patients should be informed of the warning signs and symptoms 
of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice,right 
upper quadrant tenderness and “flu-like” symptoms). If these occur, patients 
should be instructed to stop therapy and seek immediate medical therapy.</paragraph>
                        <paragraph>• Patients should be informed of the signs of an anaphylactoid reaction(e.g. 
difficulty breathing, swelling of the face or throat). If these occur, patients 
should be instructed to seek immediate emergency help (see <content styleCode="bold">
                              <linkHtml href="#section-">  WARNINGS)</linkHtml>
                           </content>.</paragraph>
                        <paragraph>• In late pregnancy, as with other NSAIDs, IBU tablets should be avoided 
because it may cause premature closure of the ductus arteriosus.</paragraph>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <content styleCode="bold">
                           <br/>Laboratory Tests</content>
                        <paragraph>Because serious GI tract ulcerations and bleeding can occur 
without warning symptoms, physicians should monitor for signs or symptoms of GI 
bleeding. Patients on long-term treatment with NSAIDs should have their CBC and 
chemistry profile checked periodically.If clinical signs and symptoms consistent 
with liver or renal disease develop, systemic manifestations occur (e.g., 
eosinophilia,rash etc.), or abnormal liver tests persist or worsen, IBU 
tabletsshould be discontinued.</paragraph>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <content styleCode="bold">
                           <br/>Drug Interactions</content>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">ACE-inhibitors:</content>Reports suggest that 
NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This 
interaction should be given consideration in patients taking NSAIDs concomitantly 
with ACE-inhibitors.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Aspirin</content> When IBU tablets are administered with 
aspirin, its protein binding is reduced, although the clearance of free IBU 
tablets is not altered. The clinical significance of this interaction is not 
known; however,as with other NSAIDs, concomitant administration of ibuprofenand 
aspirin is not generally recommended because of the potential for increased 
adverse effects.</paragraph>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <content styleCode="bold">
                           <br/>Diuretics</content>
                        <paragraph>Clinical studies, as well as post marketing observations, 
have shown that Ibuprofen tablets can reduce the natriuretic effect-of furosemide 
and thiazides in some patients. This response has been attributed to inhibition 
of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the 
patient should be observed closely for signs of renal failure (see PRECAUTIONS, 
Renal Effects), as well as to assure diuretic efficacy.</paragraph>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <content styleCode="bold">
                           <br/>Lithium</content>
                        <paragraph>Ibuprofen produced an elevation of plasma lithium levels and 
a reduction in renal lithium clearance in a study of eleven normal volunteers.The 
mean minimum lithium concentration increased 15%and the renal clearance of 
lithium was decreased by 19% during this period of concomitant drug 
administration.This effect has been attributed to inhibition of renal 
prostaglandin synthesis by ibuprofen. Thus, when ibuprofen and lithium are 
administered concurrently, subjects should be observed carefully for signs of 
lithium toxicity. (Read circulars for lithium preparation before use of such 
concurrent therapy.)</paragraph>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <content styleCode="bold">
                           <br/>Methotrexate</content>
                        <paragraph>NSAIDs have been reported to competitively inhibit 
methotrexate accumulation in rabbit kidney slices. This may indicate that they 
could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are 
administered concomitantly with methotrexate.</paragraph>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <content styleCode="bold">
                           <br/>Warfarin-type anticoagulants</content>
                        <paragraph>Several short-term controlled studies failed to show that 
Ibuprofen tablets significantly affected prothrombin times or a variety of 
other clotting factors when administered to individuals on 
coumarin-type anticoagulants. However, because bleeding has been reported when IBU 
tablets and other NSAIDs have been administered to patients on coumarin-type 
anticoagulants, the physician should be cautious when administering IBU tablets 
to patients on anticoagulants. The effects of warfarin and NSAIDs on GI bleeding 
are synergistic, such that the users of both drugs together have a risk of 
serious GI bleeding higher than users of either drug alone.</paragraph>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <content styleCode="bold">
                           <br/>H-2 Antagonists</content>
                        <paragraph>In studies with human volunteers, co-administration of 
cimetidine or ranitidine with ibuprofen had no substantive effect on 
ibuprofen serum concentrations.</paragraph>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <content styleCode="bold">
                           <br/>Pregnancy</content>
                        <paragraph>
                           <content styleCode="bold">Teratogenic effects: Pregnancy Category C</content>
                        </paragraph>
                        <paragraph>Reproductive studies conducted in rats and rabbits have not demonstrated 
evidence of developmental abnormalities. However,animal reproduction studies are 
not always predictive of human response. There are no adequate and 
well-controlled studies in pregnant women. Ibuprofen should be used in pregnancy 
only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <content styleCode="bold">
                           <br/>Nonteratogenic effects</content>
                        <paragraph>Because of the known effects of NSAIDs on the fetal 
cardiovascular system (closure of ductus arteriosus), use during late 
pregnancy should be avoided.</paragraph>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <content styleCode="bold">
                           <br/>Labor and Delivery</content>
                        <paragraph>In rat studies with NSAIDs, as with other drugs known to 
inhibit prostaglandin synthesis, an increased incidence of dystocia, 
delayed parturition, and decreased pup survival occurred. The effects of 
IBU tablets on labor and delivery in pregnant women are unknown.</paragraph>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <content styleCode="bold">
                           <br/>Nursing Mothers</content>
                        <paragraph>It is not known whether this drug is excreted in human 
milk.Because many drugs are excreted in human-milk and because of the potential 
for serious adverse reactions in nursing infants from IBU tablets, a decision 
should be made whether to discontinue nursing or discontinue the drug, taking 
into account the importance of the drug to the mother.</paragraph>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <content styleCode="bold">
                           <br/>Pediatric Use</content>
                        <paragraph>Safety and effectiveness of IBU tablets in pediatric patients 
have not been established.</paragraph>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <linkHtml href="#section-"/>
                        <content styleCode="bold">
                           <br/>Geriatric Use</content>
                        <paragraph>As with any NSAIDs, caution should be exercised in treating 
the elderly (65 years and older).</paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b66f2291-c806-4596-b539-c234e25de22c"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The most frequent type of adverse reaction occurring 
with Ibuprofen tablets is gastrointestinal. In controlled clinical trials 
the percentage of patients reporting one or more gastrointestinal 
complaints ranged from 4% to 16%.</paragraph>
                  <paragraph>In controlled studies when Ibuprofen tablets were compared to aspirin and 
indomethacin in equally effective doses, the overall incidence of 
gastrointestinal complaints was about half that seen in either the aspirin- or 
indomethacin-treated patients.</paragraph>
                  <paragraph>Adverse reactions observed during controlled clinical trials at an incidence 
greater than 1% are listed in the table. Those reactions listed in Column one 
encompass observations in approximately 3,000 patients. More than 500 of these 
patients were treated for periods of at least 54 weeks.</paragraph>
                  <paragraph>Still other reactions occurring less frequently than 1 in 100 were reported in 
controlled clinical trials and from marketing experience.These reactions have 
been divided into two categories: Column two of the table lists reactions with 
therapy with Ibuprofen tablets where the probability of a causal relationship 
exists: for the reactions in Column three, a causal relationship with Ibuprofen 
tablets has not been established.</paragraph>
                  <paragraph>Reported side effects were higher at doses of 3200 mg/day than at doses of 
2400 mg or less per day in clinical trials of patients with rheumatoid arthritis. 
The increases in incidence were slight and still within the ranges reported in 
the table.</paragraph>
                  <br/>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <br/>
                  <paragraph/>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20110322"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM2">
                     <text>Table Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="table image.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="7f7064be-cd21-47e8-a3ab-9e02c2c8b1f5"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Approximately 11⁄2 hours after the reported ingestion of from 7 
to10 Ibuprofen tablets (400 mg), a 19-month old child weighing 12 kg was seen in 
the hospital emergency room, apneic and cyanotic,responding only to painful 
stimuli. This type of stimulus, however,was sufficient to induce respiration. 
Oxygen and parenteral fluids were given; a greenish-yellow fluid was aspirated 
from the stomach with no evidence to indicate the presence of ibuprofen. Two 
hours after ingestion the child’s condition seemed stable; she still 
responded only to painful stimuli and continued to have periods of apnea 
lasting from 5 to 10 seconds. She was admitted to intensive care and sodium 
bicarbonate was administered as well as infusions of dextrose and normal saline. 
By four hours post-ingestion she could be aroused easily, sit by herself and 
respond to spoken commands.Blood level of ibuprofen was 102.9 μg/mL 
approximately 81⁄2 hours after accidental ingestion. At 12 hours she appeared to 
be completely recovered.</paragraph>
                  <paragraph>In two other reported cases where children (each weighing approximately 10 kg) 
accidentally, acutely ingested approximately120 mg/kg, there were no signs of 
acute intoxication or late sequelae.Blood level in one child 90 minutes after 
ingestion was 700 μg/mL —about 10 times the peak levels seen in 
absorption-excretion studies.A 19-year old male who had taken 8,000 mg of 
ibuprofen over a period of a few hours complained of dizziness, and nystagmus 
was noted. After hospitalization, parenteral hydration and three days bed rest, he 
recovered with no reported sequelae.</paragraph>
                  <paragraph>In cases of acute overdosage, the stomach should be emptied by vomiting or 
lavage, though little drug will likely be recovered if more than an hour has 
elapsed since ingestion. Because the drug is acidic and is excreted in the urine, 
it is theoretically beneficial to administer alkali and induce diuresis. In 
addition to supportive measures, the use of oral activated charcoal may help to 
reduce the absorption and reabsorption of Ibuprofen tablets.</paragraph>
               </text>
               <effectiveTime value="20110322"/>
            </section>
         </component>
         <component>
            <section>
               <id root="d7ffa21f-5142-4ebb-b615-1c4c83157b03"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Carefully consider the potential benefits and risks of IBU 
tablets and other treatment options before deciding to use IBU tablets. Use the 
lowest effective dose for the shortest duration consistent with individual 
patient treatment goals (see WARNINGS).<br/>
                  </paragraph>
                  <paragraph>After observing the response to initial therapy with IBU tablets, the dose and 
frequency should be adjusted to suit an individual patient’s needs.Do not exceed 
3200 mg total daily dose. If gastrointestinal complaints occur, administer IBU 
tablets with meals or milk.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Rheumatoid arthritis and osteoarthritis, including 
flare-ups of chronic disease:</content>
                  <paragraph>Suggested Dosage: 1200 mg-3200 mg daily (400 mg, 600 mg or 800 mg 
tid or qid). Individual patients may show a better response to 3200 mg daily, as 
compared with 2400 mg, although in well-controlled clinical trials patients on 
3200 mg did not show a better mean response in terms of efficacy. Therefore, when 
treating patients with 3200 mg/day, the physician should observe sufficient 
increased clinical benefits to offset potential increased risk.The dose should be 
tailored to each patient, and may be lowered or raised depending on the severity 
of symptoms either at time of initiating drug therapy or as the patient responds 
or fails to respond.In general, patients with rheumatoid arthritis seem to 
require higher doses of IBU tablets than do patients with osteoarthritis.</paragraph>
                  <paragraph>The smallest dose of IBU tablets that yields acceptable control should be 
employed. A linear blood level dose-response relationship exists with single 
doses up to 800 mg (See CLINICAL PHARMACOLOGY for effects of food on rate of 
absorption).</paragraph>
                  <paragraph>The availability of three tablet strengths facilitates dosage adjustment.In 
chronic conditions, a therapeutic response to therapy with IBU tablets is 
sometimes seen in a few days to a week but most often is observed by two weeks. 
After a satisfactory response has been achieved, the patient’s dose should be 
reviewed and adjusted as required.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Mild to moderate pain:</content>
                  <paragraph>400 mg every 4 to 6 hours as necessary for relief of pain.In 
controlled analgesic clinical trials, doses of Ibuprofen tablets greater than 400 
mg were no more effective than the 400 mg dose.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>Dysmenorrhea:</content>
                  <paragraph>For the treatment of dysmenorrhea, beginning with the earliest 
onset of such pain, IBU tablets should be given in adose of 400 mg every 4 hours 
as necessary for the relief of pain.</paragraph>
               </text>
               <effectiveTime value="20110322"/>
            </section>
         </component>
         <component>
            <section>
               <id root="b5e90b95-3f32-404e-a976-3d8ad271b7b4"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>IBU tablets are available in the following strengths, colors and 
sizes:</paragraph>
                  <paragraph>
                     <content styleCode="bold">400 mg (white, oval, debossed 4I)</content>
                  </paragraph>
                  <paragraph>  Bottles of 30         NDC 16590-124-30</paragraph>
                  <paragraph>  Bottles of 40         NDC 16590-124-40</paragraph>
                  <paragraph>  Bottles of 60         NDC 16590-124-60</paragraph>
                  <paragraph>  Bottles of 90           NDC 16590-124-90</paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>  <content styleCode="bold">600 mg (white, caplet, debossed 6I)</content>
                  </paragraph>
                  <paragraph>  Bottles of 30         NDC 16590-126-30</paragraph>
                  <paragraph>  Bottles of 56         NDC 16590-126-56</paragraph>
                  <paragraph>  Bottles of 60         NDC 16590-126-60</paragraph>
                  <paragraph>  Bottles of 84         NDC 16590-126-62</paragraph>
                  <paragraph>  Bottles of 90         NDC 16590-126-90</paragraph>
                  <paragraph>  Bottles of 100         NDC 16590-126-71</paragraph>
                  <paragraph>  Bottles of 120         NDC 16590-126-72</paragraph>
                  <paragraph>  Bptt;es pf 270        NDC 16590-126-86</paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">800 mg (white, caplet, debossed 8I)</content>
                  </paragraph>
                  <paragraph>Bottles of 30            NDC 16590-125-30</paragraph>
                  <paragraph>Bottles of 40            NDC 16590-125-40<br/>
                  </paragraph>
                  <paragraph>Bottles of 50            NDC 16590-125-50</paragraph>
                  <paragraph>Bottles of 60            NDC 16590-125-60</paragraph>
                  <paragraph>Bottles of 90            NDC 16590-125-90</paragraph>
                  <paragraph>Bottles of 100            NDC 16590-125-71<br/>
                  </paragraph>
                  <paragraph>Bottles of 120          NDC 16590-125-72</paragraph>
                  <paragraph>Store at room temperature. Avoid excessive heat 40°C (104°F).</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dr. Reddy’s Laboratories, Inc.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Bridgewater, NJ 08807 USA</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>Issued February, 2010</paragraph>
                  <paragraph>
                     <content styleCode="bold">Relabeling and Repackaging by</content>:<br/>STAT Rx USA LLC<br/>Gainesville, GA  30501<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20110322"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ba93bcc2-1ca3-47e9-9d6c-000629a0c72c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - IBUPROFEN  400 MG   TABLETS</title>
               <text>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM3"/>
                  <br/>
                  <br/>
                  <br/>
                  <br/>
                  <br/>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20111024"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM3">
                     <text>IBUPROFEN 400MG 124 Label Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="IBUPROFEN 400MG 124.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="fe1529ac-d06b-45c4-9e5f-1c4c591d271e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - IBUPROFEN  600 MG   TABLETS</title>
               <text>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM4"/>
                  <br/>
                  <br/>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20120705"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM4">
                     <text>IBUPROFEN 600MG 125 Label Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="IBUPROFEN 600MG 125.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="44e2e2d7-c456-4864-994e-fea6b8810378"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - IBUPROFEN  800 MG   TABLETS</title>
               <text>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM5"/>
                  <br/>
                  <br/>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20120705"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM5">
                     <text>IBUPROFEN 800MG 126 Label Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="IBUPROFEN 800MG 126.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>